Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 7,039 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 7,039 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.02, for a total transaction of $126,842.78. Following the completion of the transaction, the director owned 358,234 shares in the company, valued at $6,455,376.68. The trade was a 1.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Maplight Therapeutics Stock Performance

Maplight Therapeutics stock opened at $16.80 on Thursday. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $21.55. The stock’s fifty day moving average price is $17.88. The firm has a market cap of $762.27 million and a price-to-earnings ratio of -0.45.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 target price for the company. Morgan Stanley began coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 price target on the stock. Stifel Nicolaus began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective for the company. Finally, Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Maplight Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $31.00.

Institutional Trading of Maplight Therapeutics

An institutional investor recently bought a new position in Maplight Therapeutics stock. Strs Ohio acquired a new position in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,000 shares of the company’s stock, valued at approximately $53,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.